Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 18 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.85 Insider Own28.29% Shs Outstand15.38M Perf Week-8.91%
Market Cap16.60M Forward P/E- EPS next Y-0.61 Insider Trans0.00% Shs Float12.93M Perf Month-23.97%
Income-11.28M PEG- EPS next Q- Inst Own1.13% Short Float0.08% Perf Quarter-37.84%
Sales0.00M P/S- EPS this Y12.05% Inst Trans-57.09% Short Ratio0.07 Perf Half Y9.38%
Book/sh-0.12 P/B- EPS next Y16.44% ROA-207.24% Short Interest0.01M Perf Year-50.00%
Cash/sh0.15 P/C6.19 EPS next 5Y- ROE-602.40% 52W Range0.40 - 2.33 Perf YTD17.20%
Dividend Est.- P/FCF- EPS past 5Y-7.06% ROI- 52W High-60.52% Beta1.42
Dividend TTM- Quick Ratio0.84 Sales past 5Y0.00% Gross Margin- 52W Low130.00% ATR (14)0.13
Dividend Ex-Date- Current Ratio0.84 EPS Y/Y TTM20.94% Oper. Margin0.00% RSI (14)28.60 Volatility11.73% 12.15%
Employees18 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price5.25
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q28.27% Payout- Rel Volume0.21 Prev Close0.93
Sales Surprise- EPS Surprise0.00% Sales Q/Q- EarningsMay 29 Avg Volume133.05K Price0.92
SMA20-17.00% SMA50-27.41% SMA200-14.19% Trades Volume28,682 Change-1.38%
May-20-24 09:00AM
May-14-24 09:05AM
May-07-24 08:45AM
May-02-24 09:19AM
Apr-22-24 08:30AM
08:30AM Loading…
Apr-18-24 08:30AM
Apr-12-24 08:30AM
Apr-10-24 07:16PM
Apr-09-24 08:30AM
Apr-05-24 08:52PM
Feb-21-24 08:30AM
Feb-07-24 09:27AM
Jan-30-24 08:30AM
Jan-09-24 08:45AM
05:00PM Loading…
Dec-27-23 05:00PM
Dec-14-23 09:24AM
Dec-05-23 08:00AM
Dec-04-23 04:01PM
Nov-28-23 08:45AM
Nov-13-23 09:20AM
Nov-09-23 09:00AM
Nov-06-23 08:30AM
Nov-01-23 09:00AM
Oct-19-23 10:30AM
Oct-17-23 08:30AM
Oct-04-23 09:10AM
Oct-03-23 07:00AM
Oct-02-23 08:46AM
09:05AM Loading…
Sep-20-23 09:05AM
Sep-19-23 09:00AM
Sep-14-23 09:00AM
Sep-06-23 08:30AM
Aug-16-23 09:00AM
Jul-17-23 08:30AM
Jul-11-23 09:00AM
Jul-06-23 08:30AM
Jun-22-23 08:30AM
Jun-01-23 08:45AM
May-15-23 09:05AM
May-02-23 08:30AM
Apr-17-23 09:05AM
Mar-27-23 09:15AM
Mar-23-23 09:05AM
Mar-22-23 08:45AM
Mar-16-23 08:30AM
Mar-14-23 08:40AM
Feb-13-23 08:30AM
Feb-10-23 05:45AM
Feb-09-23 09:20AM
Feb-08-23 09:14AM
Feb-06-23 09:12AM
Jan-19-23 08:52AM
Dec-01-22 09:05AM
Nov-16-22 09:34AM
Nov-15-22 08:30AM
Oct-27-22 08:50AM
Oct-21-22 09:25AM
Oct-18-22 08:30AM
Oct-12-22 08:30AM
Sep-29-22 08:30AM
Sep-28-22 08:30AM
Sep-21-22 08:51AM
Sep-20-22 08:45AM
Sep-19-22 09:14AM
Aug-31-22 09:00AM
Aug-29-22 02:02PM
Aug-02-22 08:30AM
Jul-28-22 09:00AM
Jul-18-22 08:30AM
Jun-30-22 09:05AM
Jun-27-22 08:30AM
Jun-22-22 08:30AM
Jun-01-22 08:30AM
May-31-22 08:30AM
May-23-22 08:30AM
Apr-11-22 08:30AM
Apr-06-22 08:30AM
Mar-30-22 08:15AM
Mar-25-22 08:00AM
Mar-22-22 06:48PM
Mar-21-22 12:29PM
Mar-15-22 09:00AM
Mar-01-22 09:00AM
Feb-24-22 09:15AM
Feb-22-22 08:30AM
Jan-31-22 09:00AM
Jan-27-22 08:30AM
Jan-04-22 09:23AM
Dec-21-21 09:00AM
Dec-13-21 04:01PM
Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. It is involved in the 2b/3 clinical trial using its product candidate, PrimeC in patients with ALS and also commencing research into other possible indications for the drug, including Alzheimer's and Parkinson's diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.